CLOs on the Move


 
Emocha uses video technology and human engagement to empower patients to take every dose of medication as prescribed. emocha facilitates a daily touchpoint for patients in order to expand access to treatment, extend the reach of existing care teams, and retain patients in care. emocha`s turnkey, enterprise adherence solution operates through dose-by-dose observation and clinical assessment of potential administration problems, including technique and side effects. Coupled with daily engagement, support, and incentives, emocha is the first holistic solution to medication non-adherence.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.emocha.com
  • 916 North Charles Street 2120, 12nd Floor - Suite 200
    Baltimore, MD USA 21221
  • Phone: 410.864.8587

Executives

Name Title Contact Details

Similar Companies

First Med Inc

First Med Inc is a Accomac, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Midland Care Connection

Midland Care Connection is a not-for-profit, community-based organization that provides a variety of health and aging care solutions, including end-of-life care, palliative care, bereavement care, and frail elder care services.

CBD Farmhouse

CBD Farmhouse™ is committed to set standards of excellence in organic quality and affordable products from our USDA hemp farm to finished products. We take pride to inspire, educate, and empower the CBD community. This isn’t just a mission- it’s our pa...

Life Skills U

Life Skills U is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.